Dasatinib treatment long-term results among imatinib-resistant/intolerant patients with chronic phase chronic myeloid leukemia are favorable in daily clinical practice.

Daniela Zackova,Hana Klamová,Petra Bělohlávková,Lukáš Stejskal,Tereza Nečasová,Lukáš Semerád,Barbora Weinbergerová,Dana Srbova,Jaroslava Voglová,Petra Čičátková,Zuzana Šustková,Tomáš Horňák,Jana Baranová,Jirina Prochazkova,Jiri Mayer

Dasatinib treatment long-term results among imatinib-resistant/intolerant patients with chronic phase chronic myeloid leukemia are favorable in daily clinical practice.

2020

Daniela Zackova
Hana Klamová
Petra Bělohlávková
Lukáš Stejskal
Tereza Nečasová
Lukáš Semerád
Barbora Weinbergerová
Dana Srbova
Jaroslava Voglová
Petra Čičátková
Zuzana Šustková
Tomáš Horňák
Jana Baranová
Jirina Prochazkova
Jiri Mayer

To evaluate long-term real-life results of dasatinib therapy among chronic phase chronic myeloid leukemia patients resistant or intolerant to imatinib, we retrospectively analyzed data of 118 patie...

Keywords:

Internal medicine
Chronic phase chronic myeloid leukemia
Oncology
Dasatinib
Clinical Practice
Toxicity
long term results
Imatinib
second line
Pleural effusion
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations